Loading...
Please wait, while we are loading the content...
Similar Documents
GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration.
| Content Provider | Europe PMC |
|---|---|
| Author | Kropp, Martina Harmening, Nina Bascuas, Thais Johnen, Sandra De Clerck, Eline Fernández, Verónica Ronchetti, Mattia Cadossi, Ruggero Zanini, Cristina Scherman, Daniel Ivics, Zoltán Marie, Corinne Izsvák, Zsuzsanna Thumann, Gabriele |
| Editor | Matrone, Carmela |
| Copyright Year | 2022 |
| Abstract | The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade manufacturing including suitable quality controls. This is challenging for Advanced Therapy Medicinal Products (ATMP) with personalized batches. We have developed a person-alized, cell-based gene therapy to treat age-related macular degeneration and established a vali-dation strategy of the GMP-grade manufacture for the ATMP; manufacturing and quality control were challenging due to a low cell number, batch-to-batch variability and short production duration. Instead of patient iris pigment epithelial cells, human donor tissue was used to produce the transfected cell product (“tIPE”). We implemented an extended validation of 104 tIPE productions. Procedure, operators and devices have been validated and qualified by determining cell number, viability, extracellular DNA, sterility, duration, temperature and volume. Transfected autologous cells were transplanted to rabbits verifying feasibility of the treatment. A container has been engineered to ensure a safe transport from the production to the surgery site. Criteria for successful validation and qualification were based on tIPE’s Critical Quality Attributes and Process Parameters, its manufacture and release criteria. The validated process and qualified operators are essential to bring the ATMP into clinic and offer a general strategy for the transfer to other manufacture centers and personalized ATMPs. |
| Journal | Biomedicines |
| Volume Number | 10 |
| PubMed Central reference number | PMC9687277 |
| Issue Number | 11 |
| PubMed reference number | 36359296 |
| e-ISSN | 22279059 |
| DOI | 10.3390/biomedicines10112777 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-11-01 |
| Access Restriction | Open |
| Rights License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). © 2022 by the authors. |
| Subject Keyword | personalized medicine autologous regenerative medicine cell product cell therapy Advanced Therapy Medicinal Product (ATMP) Good Manufacturing Practice (GMP) quality control non-viral gene therapy age-related macular degeneration (AMD) iris pigment epithelial cells (IPE) |
| Content Type | Text |
| Resource Type | Article |
| Subject | Medicine Biochemistry, Genetics and Molecular Biology |
